group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	overall survival (OS)	1034	1208	After a median follow-up of 42 months, median PFS was 10.2 and 10.8 months (p = 0.74), while median OS was 20.0 and 25.3 months (p = 0.099), for groups A and B, respectively.
group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	progression-free survival (PFS)	1034	1208	After a median follow-up of 42 months, median PFS was 10.2 and 10.8 months (p = 0.74), while median OS was 20.0 and 25.3 months (p = 0.099), for groups A and B, respectively.
group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	neutropenia and diarrhea	18380	18537	The most common (group A vs group B) were neutropenia (13% vs 22%, Fisher's exact test, p = 0.053) and diarrhea (19% vs 11%, Fisher's exact test, p = 0.082).
group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	overall survival (OS)	18016	18130	Median OS was 20 months (95% CI: 15.4–24.6) in group A and 25.3 months (95% CI: 22.1–28.6) in group B (p = 0.099).
group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	Vomiting	18538	18620	Vomiting was more frequent with XELIRI (5% vs 0%, Fisher's exact test, p = 0.014).
group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	neutropenia and diarrhea	1209	1343	Most frequent grade 3–4 toxicities (group A vs group B) were neutropenia (13% vs 22%, p = 0.053) and diarrhea (19% vs 11%, p = 0.082).
group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab)	group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab)	progression-free survival (PFS)	17878	18015	Median PFS was 10.2 months (95% confidence intervals [CI]: 9.0–11.5) in group A and 10.8 months (95% CI: 9.7–11.8) in group B (p = 0.74).
